Arcutis Biotherapeutics ARQT
NASDAQ ARQT
$23.90 +0.24 (+1.01%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arcutis Biotherapeutics (ARQT) Free Cash Flow Growth (3y) (2022 - 2026)

Analysis

Arcutis Biotherapeutics (ARQT) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -1.95%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -20.15%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 21.16%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 45.09%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 80.69%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -4.45%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 8.92%
10 Arcutis Biotherapeutics 3.12 Bn 2.88 Bn 118.92 Mn 29.85%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 29.85%
Mar 31, 2026 26.53%
Dec 31, 2025 33.29%
Sep 30, 2025 70.41%
Jun 30, 2025 26.08%
Mar 31, 2025 18.43%
Dec 31, 2024 75.68%
Sep 30, 2024 5.31%
Jun 30, 2024 -7.94%
Mar 31, 2024 12.24%
Dec 31, 2023 -19.79%
Sep 30, 2023 -9.23%
Jun 30, 2023 -37.33%
Mar 31, 2023 -56.33%
Dec 31, 2022 -61.62%
Sep 30, 2022 -84.81%
Jun 30, 2022 -95.66%
Mar 31, 2022 -98.89%